PharmaRolly Investment Summit: Unlocking the European Cannabis Market

Hosted by PharmaRolly
July 10, 2024
11:00 AM - 12:00 PM ET
Webcast

Join us for an exclusive virtual summit where PharmaRolly Holdings B.V., a leader in THC-dominant medical cannabis, will unveil unparalleled investment opportunities in the rapidly growing European cannabis market. This event is designed to provide you with key insights into PharmaRolly's strategic positioning, robust infrastructure, and experienced management team, all poised to deliver significant returns.

  • Exclusive Insights: Gain insider knowledge from PharmaRolly's CEO and management team on market trends and growth strategies.
  • High-Yield Opportunities: Explore lucrative investment options within the expanding European cannabis sector.
  • Regulatory Advantages: Understand the compliance and regulatory benefits that make Europe a prime market.
  • Strategic Expansion: Discover PharmaRolly's plans for cultivation expansion and entry into new markets.
  • Interactive Q&A: Engage directly with company leaders to get your investment questions answered in real-time.

PharmaRolly Holdings B.V.

PharmaRolly Holdings B.V., a trailblazer in the THC-dominant medical cannabis industry, and take ...

Speaker

  • Stephen Malloy

    Title
    Founder & CEO
    @
    Company
    PharmaRolly
    Role
    Speaker

    Malloy is the founder and CEO of PharmaRolly Holdings B.V., which is comprised mainly of a small number of institutional and UHNW investors. Mr. Malloy has over 26 years of international management and investment experience. Mr. Malloy has founded, managed and held senior roles at various successful global companies. Mr. Malloy has worked with pension funds, consultants, ultra high net worth individuals, family offices and other institutions.

About

PharmaRolly

PharmaRolly, a Dutch company operating at the highest international standards, is the only operator to elevate fully organic living soil-grown craft cannabis to a commercialized, standardized, and purified end product at the most competitive prices in Europe – putting patient access to organic medicine first.